IntelGenx Technologies (TSXV:IGX; OTCQB:IGXT) named Dr. Srinivas (Srini) Rao, M.D., Ph.D., and Frank Stegert to the board, reflecting a previously disclosed purchaser rights agreement with atai Life Sciences AG.
With the appointments, the size of the IntelGenx board increases to eight from six.
Dr. Rao has served as atai’s CSO since April 2019 and Mr. Stegert as atai’s VP of investment management and operations since January 2021.
Dr. Rao has been assigned to the compensation committee of the board and Mr. Stegert has been assigned to the corporate governance and nominations committee of the board.
